CII-PwC report: 77% Indian households use ayurvedic products

Increased emphasis on lifestyle and wellness, driven by a rise in non-communicable and chronic diseases, is driving the demand for ayurveda in India, according to a report by Confederation of Indian Industry (CII) and Pricewaterhouse-Coopers (PwC). The report said 77% of Indian households used ayurvedic products in 2017, up from 69% in 2015. The global market for ayurveda is estimated to almost treble from $3.4-bn in 2015 to $9.7-bn by 2022.
The report calls for a paradigm shift in core ayurvedic industries using technology as an enabler, to meet the increasing demand. It emphasises the need for standardisation and quality control to launch ayurveda on a global scale.
Key role for Kerala
Kerala is well positioned to cater to this rising demand for ayurvedic products and services. The state is singularly advantaged in its ability to deliver ayurvedic products and services, in all segments of ayurveda, the report said.
Kerala, known as the cradle of ayurveda, has many advantages when it comes to ayurveda. The state’s core capabilities are strengthened by a range of products and services, advancements in research and education, increase in tourism and strong support from the government. Thanks to these advantages, Kerala is well on the way to becoming a hub for investment in ayurveda, and companies making and marketing ayurvedic medicines, the report added.
Kerala had 1,400 ayurveda-associated industries with a total turnover of $37-mn and export of $8.3-mn in 2016. It accounts for 10% of the Indian herbal industry of $578-mn.
Looking for chemical products? Let suppliers reach out to you!
2026-06-26
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
FDA Fee Updates Raise the Cost of Entering the U.S. Generic Drug Chain
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24
-
Zydus Lifesciences Blocked by Delhi High Court in Cancer Biosimilar Case $9.3 Billion Opdyta Patent Dispute Intensifies
Recommend Reading
-
Novartis Boosts 2025 Earnings Forecast as US Tariff Risks Loom $23 Billion Investment and $10 Billion Buyback Unveiled
-
Bristol Myers’ Reblozyl Misses Main Goal in Cancer Anemia Study $1.77 Billion Drug Faces Setback but Shows Some Benefits
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
Obesity Drugs Become Pharma’s Most Powerful Growth Engine
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
-
DMF Market Primarily Operates Strongly
-
Sika Acquires Qatari Construction Chemicals Company Gulf Additive Factory
-
Cyclohexane Market Prices Mainly Stable in China
-
AkzoNobel India Changes Ownership
-
The Truth Behind the US-China Trade "Truce": Rare Earths Game Intensifies, China’s Chemical Market Sees Explosive Opportunities!